Home > Boards > US Listed > Biotechs > Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN)

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
conix Member Profile
 
Followed By 169
Posts 26,511
Boards Moderated 9
Alias Born 10/10/05
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/28/2020 5:07:17 PM
Regeneron, Sanofi Get FDA Priority Review of Dupixent in Children With Atopic Dermatitis Dow Jones News - 1/28/2020 6:30:00 AM
FDA Accepts for Priority Review Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermati... PR Newswire (US) - 1/28/2020 12:59:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/27/2020 4:05:24 PM
Forty of the Nation's Brightest Young Scientists Named Finalists in Regeneron Science Talent Search 2020 PR Newswire (US) - 1/22/2020 12:01:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/13/2020 9:16:18 AM
Regeneron to Report Fourth Quarter and Full Year 2019 Financial and Operating Results and Host Conference Call and Webcast on... PR Newswire (US) - 1/10/2020 7:00:00 AM
Regeneron Announces Encouraging Garetosmab Phase 2 Results in Patients with Ultra-Rare Debilitating Bone Disease PR Newswire (US) - 1/9/2020 7:00:00 AM
Publication Highlights Regeneron's Costimulatory Bispecific Antibodies, an Emerging Class of Cancer Immunotherapy PR Newswire (US) - 1/8/2020 2:02:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/6/2020 4:08:17 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/6/2020 4:06:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/6/2020 4:05:05 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/6/2020 4:04:48 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/6/2020 4:04:28 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/6/2020 4:04:12 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/6/2020 4:03:56 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/6/2020 4:03:30 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/6/2020 4:02:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/23/2019 4:03:23 PM
Regeneron Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference PR Newswire (US) - 12/20/2019 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/18/2019 4:05:58 PM
GlaxoSmithKline: Study Shows Blood Cancer Drug Works in Heavily Treated Patients Dow Jones News - 12/16/2019 6:59:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/13/2019 6:03:51 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/13/2019 5:44:41 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/13/2019 4:45:43 PM
conix   Thursday, 11/29/18 11:13:16 AM
Re: TREND1 post# 133
Post # of 137 
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN)

Total board compensation: $23.88 million

Average compensation per board member: $2.17 million

Successful Trading is the art of minimizing long term risk and maximizing capital allocation.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist